Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

In addition, in the coming years, oral GLP-1 receptor agonists and injectable formulations that require less-frequent ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

“Madrigal is doing a lot of work for us,” said Frederic Cren, CEO of Inventiva Pharma, which has its own oral MASH drug ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

GLP-1 RAs are known to delay gastric emptying ... prompting the ASA in 2023 to recommend holding these agents for 1 week for ...